You are here
Pantoprazole Sodium Provides Effective Gastric Acid Suppression at Reduced Infusion Times
NEW ORLEANS, May 17 /PRNewswire/ -- Two-minute infusions of pantoprazole sodium for injection are as effective as 15-minute infusions in suppressing gastric acid in patients with gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, according to a study presented in New Orleans at the Digestive Disease Week annual meeting.
"These data are welcome news to hospital pharmacists and nurses," said Dr. Pisegna, Chief, Division of Gastroenterology and Hepatology VA, Greater Los Angeles Health Care Center and Associate Professor of Medicine in Residence at the David Geffen School of Medicine at UCLA. "The 2-minute formulation may reduce drug preparation time and administration costs in hospitals, since the intravenous admixture bag can be replaced with a less expensive syringe for administration."
The study demonstrated that pantoprazole sodium for injection reduced acid volume and output when given either over two or 15 minutes to elective surgical patients. Both the median acid volume and median acid output were lower than the baseline values, regardless of the dosing regimen used or the length of the infusion.
Specifically, patients who received either 2 or 15 minute infusions of doses of 40 mg IV therapy either once a day or every 12 hours significantly reduced their median acid volume six to 12 hours after surgery, compared to the same infusion times for 80 mg doses given every 12 hours. Also, patients receiving the two-minute infusions of either 40 mg IV therapy significantly reduced their median acid output six to 12 hours after surgery, compared to other formulations.
About Pantoprazole Sodium for Injection
Pantoprazole sodium for injection has established a high standard of care for intravenous acid suppressant therapy and is currently used in more than 5,000 hospitals worldwide. It is currently indicated for the short-term, treatment (7 to 10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral therapy in patients who are unable to continue taking pantoprazole sodium Delayed-Release Tablets.
It also is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.
The study is funded by Wyeth Laboratories, Inc., that manufactures pantoprazole sodium.
About the UCLA Division of Digestive Diseases
The UCLA Division of Digestive Diseases has advanced the field with discoveries and clinical expertise in many areas. The division is world-renowned for clinical as well as basic science research. Achievements include the first hepatitis B immune globulin; the first description of hepatitis C, the most common form of viral hepatitis; discovery of a new generation of ulcer medications that inhibits stomach acid production; and development of new treatments for irritable bowel syndrome. In addition, the division is recognized worldwide for its expertise in liver transplantation, management of chronic liver disease and irritable bowel syndrome, endoscopic treatment of gastrointestinal bleeding, and diagnosis of gastrointestinal diseases by endoscopic biopsy.
Source: UCLA Division of Digestive Diseases